Cerecin, Inc.

Titled "The Potential of Fasting and Diet in the Future of Medicine" Highlighting the Potential of Ketones - from Fasting, the Ketogenic diet and Pharmaceuticals - to Address Neurological Disease and Improve Brain Health DENVER, Colo., March 5, 2026 /PRNewswire/ -- Cerecin Inc., a clinical-stage biotechnology company developing metabolic drugs for neurological disorders, today announced that Dr. Charles Stacey, Chief Executive Officer of Cerecin, delivered a TEDx talk at TEDxNTU Singapore in October 2025, and the talk is now available to view online. Continue Reading The TEDx talk, “The Potential of Fasting and Diet in the Future of Medicine,” by Dr. Charles Stacey Speed Speed Dr Stacey speaking at TEDxNTU Titled "The Potential of Fasting and Diet in the Future of Medicine" Dr. Stacey's TEDx talk explores the frontier science of brain energy metabolism, how the brain's high demand for fuel and its vulnerability to energy deficits may contribute to neurological disease, and how ketones, produced during fasting and ketosis, represent an alternative energy source with potential benefit in conditions such as Alzheimer's disease and epilepsy. The TEDx talk, "The Potential of Fasting and Diet in the Future of Medicine," by Dr. Charles Stacey (TEDxNTU, October 2025) is now available to view online: In the talk, Dr. Stacey describes how the brain, despite representing only ~2% of body weight, consumes up to ~20% of the body's energy, and how imaging and clinical research show that impaired glucose metabolism may be an early and important feature of neurodegenerative and neurological disorders. He explains that when glucose availability declines, the body can shift to producing ketone bodies, derived from fat, which can cross into the brain and be converted into energy, a highly conserved biological pathway. "If a failing brain is, at its core, an under-fuelled brain, then perhaps the solution is to give it more energy—not by simply adding more glucose, but by restoring brain bioenergetics," said Dr. Charles Stacey, CEO of Cerecin. "This TEDx talk is about the potential of ketones—the physiological emergency fuel the brain—and how translating the biology of fasting into precision pharmacology is opening a new frontier in brain health." Dr. Stacey also highlights historical and medical observations linking fasting and ketogenic states to seizure control, including early clinical reports that inspired the modern ketogenic diet, and describes how biotech companies at the forefront of modern neuroscience, such as Cerecin, are working to create oral, controlled, and sustainable medicines that deliver the metabolic benefits of ketosis without the burden of strict dietary intervention. Cerecin is developing a pipeline of neurometabolic assets that target brain energy metabolism. CER-0001 (tricaprilin) and CER-081 are first-in-class ketogenic drug candidates. CER-0001 is in late-stage development for Alzheimer's disease and is also being advanced for rare pediatric epilepsies also known as Developmental and Epileptic Encephalopathies (DEEs). Cerecin is also developing CER-022, an investigational radiolabelled tracer for positron emission tomography (PET) imaging of ketone metabolism. "Cerecin is at the forefront of a growing field in neuroscience that focuses on energy as a foundational driver of brain function," said Samuel Henderson, PhD, Chief Scientific Officer of Cerecin. Dr. Henderson, who has more than 20 years of experience in neurodegenerative disease research and a PhD in molecular genetics and cell biology from the University of Chicago, leads Cerecin's scientific strategy in neurometabolism and metabolic therapeutics "We are pleased to support Dr. Stacey's effort to share a science-based perspective on ketones, fasting biology, and the potential to develop metabolic therapies that may help address major unmet needs in neurological disease." Disclaimer The TEDx talk reflects Dr. Charles Stacey's personal views and perspectives shared in a public forum and does not necessarily represent the views, positions, or strategies of Cerecin. References to scientific concepts are provided for general educational discussion and should not be interpreted as medical advice or as claims regarding the safety or efficacy of any investigational product. About TEDx In the spirit of ideas worth spreading, TEDx is a program of local, self-organized events that bring people together to share a TED-like experience. At a TEDx event, TED Talks video and live speakers combine to spark deep discussion and connection. These local, self-organized events are branded TEDx, where **x = independently organized TED. TEDxNTU 2025, hosted by Nanyang Technological University in Singapore, is one of the region's flagship TEDx events and draws a live audience of several thousand attendees from academia, industry, and the public. About Cerecin Cerecin is a biopharmaceutical company focused on the development and commercialization of drugs to improve brain health. Cerecin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of ketosis. Cerecin is led by an expert executive management team with strong global expertise in central nervous system drug development and supported by two partners, Nestlé and Wilmar, one of the world's leading manufacturers and traders of fatty acids and lipids. Bringing together the deep industry expertise of its leadership team and a highly differentiated portfolio, Cerecin is growing its global presence to serve the brain health needs of patients and people across the world. Media Contact Cerecin Inc. [email protected] SOURCE Cerecin Inc. 21% more press release views with Request a Demo

Study showed that the investigational ketogenic drug was generally well tolerated and demonstrated seizure reduction in infants with rare drug-resistant epileptic spasms. Phase 1/2a study supports further development as a metabolic therapy for rare developmental and epileptic encephalopathy (DEE). DENVER, Feb. 26, 2026 /PRNewswire/ -- Cerecin Inc., a clinical-stage biotechnology company developing metabolic drugs for neurological disorders, today announced the publication of a Phase 1/2a clinical study evaluating the investigational drug CER-0001 (tricaprilin) for the treatment of refractory infantile epileptic spasms, a rare and devastating form of early-onset epilepsy. The study, titled "Ketogenic drug tricaprilin (CER-0001) for the treatment of refractory infantile epileptic spasms: a phase 1/2a study," was published in Frontiers in Pediatrics on February 20, 2026. Infantile epileptic spasms, also known as West Syndrome, affect infants typically between 3 and 24 months of age and are associated with developmental delay and long-term neurological disability. Despite available treatments, approximately 40–60% of patients do not respond adequately to first-line therapies, highlighting the urgent need for new treatment options. CER-0001 is an investigational ketogenic drug designed to induce therapeutic ketosis without requiring strict dietary restrictions. Unlike traditional ketogenic diets, CER-0001 can be administered as a prescription oral therapy, potentially expanding access to metabolic treatment approaches. Promising Early Clinical Results The Phase 1/2a open-label study enrolled eight infants with drug-resistant infantile epileptic spasms across clinical sites in Australia and Singapore. The study demonstrated that CER-0001 may provide a novel pharmacological approach to ketogenic therapy without the burden of strict dietary intervention. "Rare epilepsies such as infantile epileptic spasms represent a major unmet medical need," said Samuel Henderson, PhD, Chief Scientific Officer of Cerecin . "These results support the potential of CER-0001 as a practical metabolic therapy that could provide the benefits of ketosis without the challenges of a ketogenic diet. On Rare Disease Day, we reaffirm our commitment to developing metabolic therapies that address the needs of patients with rare neurological disorders." The results support further clinical development, and a larger randomized controlled study is planned to confirm the therapeutic potential of CER-0001 in developmental and epileptic encephalopathies. Commitment to Rare Disease Patients Rare Disease Day highlights the importance of innovation for patients living with uncommon and often severe conditions. Cerecin is developing metabolic medicines designed to address the underlying energy deficits present in a range of neurological diseases, including rare epilepsies. About CER-0001 CER-0001 (tricaprilin) is an investigational oral ketogenic drug designed to elevate ketone bodies and provide an alternative energy source for the brain. CER-0001 is being developed as a prescription therapy for neurological disorders including rare epilepsies, Alzheimer's disease, and migraine. CER-0001 has not been approved by any regulatory authority. About Cerecin Cerecin is a biopharmaceutical company focused on the development and commercialization of drugs to improve brain health. Cerecin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of ketosis. Cerecin is led by an expert executive management team with strong global expertise in central nervous system drug development and supported by two partners, Nestlé and Wilmar, one of the world's leading manufacturers and traders of fatty acids and lipids. Bringing together the deep industry expertise of its leadership team and a highly differentiated portfolio, Cerecin is growing its global presence to serve the brain health needs of patients and people across the world. Media Contact Cerecin Inc. [email protected] SOURCE Cerecin Inc. 21% more press release views with Request a Demo

1、研究机构：Cerecin 2、别名：NOF-005、AC-SD-01、AC-1202、AC-LMP-01、AC-SD-03、AC-1204、AC-OLE、Ketasyn、Axona、三辛酸甘油酯 3、靶点：HMGB1 4、剂型及给药途径：散剂; 口服给药 5、结构式： 6、适应症 适应症 进展 最新进展日期 偏头痛 II期 2024-07-22 阿尔兹海默病 III期 2023-10-19 West综合症 I期 2023-12-04 7、专利布局 公开（公告）号 专利主题 发明名称 申请日 法律状态 CN101809443B 用途 基因组测试和生酮化合物用于治疗降低的认知功能的用途 2008-07-31 CN110769814B 制剂 具有高载药量的中链甘油三酯的药物组合物及其相关方法 2018-03-15 CN112566629B 制剂 具有高药物装载的中链甘油三酯的药物组合物及其相关方法 2019-03-15 CN113507926A 制剂 具有改善的生物利用度的中链甘油三酯制剂及其有关方法 2020-03-04 实质审查 CN115884766A 用途 用于使用中链甘油三酯治疗婴儿痉挛的方法 2021-05-28 实质审查 CN117460495A 制剂 具有高载药量的中链甘油三酯的稳定液体药物组合物及其相关方法 2022-05-25 实质审查 8、研究历程 2023年04月14日，治疗阿尔茨海默病的研究终止。（NCT04187547） 2022年06月30日，由Cerecin Inc开展临床三期试验，用于治疗阿尔茨海默病。（NCT04187547） 2021年11月01日，由Cerecin Inc在澳大利亚和新加坡开展临床一期试验，用于治疗婴儿痉挛。（NCT04727970） 2020年12月17日，由Cerecin Inc在澳大利亚开展临床二期试验，用于治疗偏头痛。（NCT04437199） 2020年07月10日，由艾昆纬医药科技（上海）有限公司向中国国家药品监督管理局NMPA提交IND申请。（ JXHL2000212; JXHL2000211） 2020年02月27日，由Cerecin Inc在美国开展临床一期试验，用于治疗阿尔茨海默病。（NCT04268953; NCT05408780） 2019年08月30日，由Cerecin Inc在澳大利亚开展临床一期试验，用于治疗阿尔茨海默病。（NCT05028114; NCT03971123; NCT05628636） 2019年02月13日，由Cerecin Inc开展临床一期试验，用于治疗阿尔茨海默病。（NCT03635879） 2017年06月26日，临床一期研究暂无进展。（NCT02747602; NCT03063645; NCT02833012; NCT02959710） 2017年05月16日，治疗阿尔茨海默病的研究终止。（NCT01741194; NCT01211782） 2016年04月01日，由Cerecin Inc在美国开展临床一期试验。（NCT02747602; NCT03063645; NCT02833012; NCT02959710） 2010年09月24日，由Cerecin Inc在美国开展临床三期试验，用于治疗阿尔茨海默病。（NCT01741194; NCT01211782） 2004年11月04日，由Cerecin Inc在美国开展临床二期试验，用于治疗阿尔茨海默病。（NCT00142805） 9、临床试验 登记号 试验标题 试验药 对照药 适应症 原始适应症 申办/合作机构 试验状态 试验分期 开始日期 完成日期 国家/地区 NL-OMON57242 The role of a nutritional formulation containing caprylic acid and omega 3 fatty acids in promoting skeletal muscle function recovery to damaging exercise in healthy, young volunteers - RECOVER 三辛酸甘油酯 - - Recovery of muscle function and muscle soreness after damaging exercise | 10028302 Wageningen Universiteit Holding BV Suspended N/A 2025-08-01 - 荷兰 NCT05809908 A Phase 3, 26-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Daily Administration of Tricaprilin as AC-OLE-01-VA in Participants With Mild to Moderate Alzheimer's Disease Dementia 三辛酸甘油酯 (口服) - 阿尔茨海默症 Alzheimer Disease Cerecin, Inc. Not yet recruiting 临床3期 2026-06-01 2029-01-01 - NCT05628636 A Phase 1, Open-label Study to Evaluate the Tolerability of 21 Days of Treatment With the AC-OLE-01-VA Formulation of Tricaprilin Under Different Dosing Conditions in Healthy Participants 三辛酸甘油酯 - 阿尔茨海默症 Alzheimer Disease Cerecin, Inc. Completed 临床1期 2022-11-14 2023-04-03 澳大利亚 NCT05408780 A Phase 1, Two-part, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Liquid Formulation of Tricaprilin, and Matching Placebo to Include Single-dose and Food Effect (Part A), and Titration Tolerability (Part B), in Healthy Subjects 三辛酸甘油酯 (液体) - 阿尔茨海默症 Alzheimer Disease Cerecin, Inc. Completed 临床1期 2022-07-14 2022-10-24 美国 NCT05028114 A Phase 1, Three-part, Part-randomised, Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Different Formulations of Tricaprilin, to Include Single-dose, Food Effect, and Titration Tolerability, in Healthy Participants 三辛酸甘油酯 (液体) - 阿尔茨海默症 Alzheimer Disease Cerecin, Inc. Terminated 临床1期 2021-08-31 2022-07-19 澳大利亚 NCT04727970 A Phase I Open-Label Pilot Study to Investigate the Feasibility, Safety, Tolerability and Efficacy of Daily Administration of Tricaprilin in Subjects with Infantile Spasms 三辛酸甘油酯 - 婴儿痉挛 Infantile Spasm Cerecin, Inc. Completed 临床1期 2021-11-01 2023-12-04 新加坡 | 澳大利亚 NCT04437199 A 12-Week, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Investigate the Efficacy and Safety of Daily Administration of Tricaprilin as AC-SD-03 in Participants With Migraine 三辛酸甘油酯 (粉剂) - 偏头痛 Migraine Cerecin, Inc. Completed 临床2期 2020-12-17 2022-02-07 澳大利亚 NCT04268953 A Phase 1, Single-centre, Multiple-dose, Open-label Study to Assess the Safety, Tolerability, and Pharmacokinetics of the AC-SD-03 Formulation of Tricaprilin in Healthy Older Volunteers 三辛酸甘油酯 - 阿尔茨海默症 Alzheimer Disease Cerecin, Inc. Completed 临床1期 2020-02-27 2020-05-01 美国 NCT04187547 A Phase III, 26-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Trial to Investigate the Efficacy and Safety of Daily Administration of Tricaprilin as AC-SD-03 in Subjects With Mild to Moderately Severe Probable Alzheimer's Disease and Who Are Noncarriers of the APOE4 Allele 三辛酸甘油酯 - 阿尔茨海默症 Alzheimer's Disease Cerecin, Inc. Withdrawn 临床3期 2022-06-30 2024-02-28 - NCT03971123 A Phase 1, Randomised, Single-center, Single-dose, Placebo-controlled, 3-Way Crossover Study to Compare the Pharmacokinetics, Safety and Tolerability of a Lipid Multi-particulate (LMP) Formulation and Spray-dried (SD) Formulations of Tricaprilin (TC) on Ketone Body Production (Part 1). Addendum to Include a 2-way Crossover to Compare the Pharmacokinetics, Safety and Tolerability of Two Spray-dried (SD) Formulations of Tricaprilin (TC) on Ketone Body Production (Part 2) 三辛酸甘油酯 - 阿尔茨海默症 Alzheimer Disease Cerecin, Inc. Completed 临床1期 2019-08-30 2020-05-26 澳大利亚 NCT03635879 A Phase 1, Single-Center, Pilot, Single-Dose, 6-Way Crossover Study to Compare Six Formulations of Medium Chain Triglycerides on the Pharmacokinetics of Ketone Body Production 三辛酸甘油酯 三辛酸甘油酯 阿尔茨海默症 Alzheimer Disease Cerecin, Inc. Withdrawn 临床1期 2019-02-13 2019-04-16 - NCT03628352 An Open-Label Taste Assessment of Tricaprilin Formulated as a Powder for Reconstitution in Healthy Panelists 三辛酸甘油酯 - 味觉障碍 Taste Profile Assessments Cerecin, Inc. Completed 临床1期 2018-09-10 2019-08-22 美国 NCT03551769 A Phase I, Open-label, Fixed-order, Single-dose, 2-Part, Crossover Study to Evaluate the Pharmacokinetics of a Formulation of Tricaprilin (AC-SD-01) Including the Effect of Food on Ketone Body Production in Caucasians and Asians 三辛酸甘油酯 - 阿尔茨海默症 Alzheimer Disease Cerecin, Inc. Completed 临床1期 2018-08-05 2018-08-27 澳大利亚 NCT03223389 Effects of Fat Metabolites on Gut Hormone Secretion After Gastric Bypass Surgery 三辛酸甘油酯 - 2型糖尿病 | 脂质代谢紊乱 | 肥胖 Overweight and Obesity | Type 2 Diabetes | Bariatric Surgery | Gut Hormones | Dietary Fat Hvidovre University Hospital | University of Copenhagen Unknown status N/A 2017-08-07 2018-12-01 丹麦 NCT03063645 A Phase 1, Pilot, Single-Dose, 3-Way Crossover Study to Compare the Pharmacokinetics of AC 1202 and Two Doses of AC-SD-01 on Ketone Body Production 三辛酸甘油酯 - - Healthy Cerecin, Inc. | Celerion, Inc. Completed 临床1期 2017-03-11 2017-05-05 美国 NCT02959710 A Phase 1, Pilot, Single-Dose, 3-Way Crossover Study to Compare the Pharmacokinetics of AC-1204 Mixed in Water, AC-1202 Mixed in Water, and AC-1202 Mixed in Ensure® on Ketone Body Production 三辛酸甘油酯 - - Healthy Cerecin, Inc. | Celerion, Inc. Completed 临床1期 2016-11-01 2017-04-01 美国 NCT02833012 A Phase 1, Pilot, Single-Dose, 4-Way Crossover Study to Compare the Pharmacokinetics of Caprylic Triglyceride Oil, AC-1202, AC-1204, and Axona on Ketone Body Production 三辛酸甘油酯 - - Healthy Cerecin, Inc. | Celerion, Inc. Completed 临床1期 2016-07-01 2016-12-01 美国 NCT02747602 A Phase 1, Pilot, Single-Dose, 3-Way Crossover Study to Evaluate the Pharmacokinetic of AC-1204 Versus Caprylic Triglyceride Oil Including the Effect of Food on Ketone Body Production 三辛酸甘油酯 - - Healthy Cerecin, Inc. | Celerion, Inc. Completed 临床1期 2016-04-01 2016-10-01 美国 NCT02716662 Safety of Caprylic Triglycerides in ALS: A Pilot Study 三辛酸甘油酯 - 肌萎缩侧索硬化 ALS Weill Medical College of Cornell University Completed N/A 2016-01-01 2018-04-25 美国 NCT02679222 Comparing the Ketogenic Effect of Coconut Oil and Different Medium-chain Triglycerides 三辛酸甘油酯 - - Healthy Adults University of Sherbrooke Completed N/A 2015-06-01 2017-03-01 加拿大 NCT01848327 A Randomized Double-Blind Placebo-Controlled Study of Caprylic Triglyceride for Cognitive Impairment in Subjects With Multiple Sclerosis. 三辛酸甘油酯 - 认知功能障碍 | 原发性进行性多发性硬化 | 继发进展型多发性硬化 | 复发-缓解型多发性硬化 Relapsing Remitting MS | Secondary Progressive MS | Primary Progressive MS University of Miami | Cerecin, Inc. | The National Multiple Sclerosis Society Completed N/A 2013-02-01 2017-12-01 美国 NCT01741194 A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension 三辛酸甘油酯 - 阿尔茨海默症 Alzheimer's Disease Cerecin, Inc. Completed 临床2/3期 2013-03-01 2017-04-14 美国 NCT01211782 A Phase 2-3, 6-12 Month, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Subjects With Mild to Moderate Alzheimer's Disease Who Are APOE4(-) 三辛酸甘油酯 - 阿尔茨海默症 Alzheimer's Disease Cerecin, Inc. Withdrawn 临床2/3期 - - 美国 NCT00660088 Tolerability, Safety, And Pharmacokinetics Of Three Formulations Of Oral Ketasyn™ (Ac-1202) Administered For Fourteen Days, With Or Without Titration, In Healthy Elderly Volunteers 三辛酸甘油酯 - 阿尔茨海默症 Alzheimer's Disease Cerecin, Inc. Completed N/A 2008-04-01 2008-08-01 美国 NCT00355550 A Double-Blind, Placebo-Controlled Study of Tricaprilin (AC-1202) Administered For Ninety Days In Subjects With Age-Associated Memory Impairment 三辛酸甘油酯 - 遗忘 Age-Associated Memory Impairment Cerecin, Inc. Completed 临床2期 2006-07-01 2007-06-01 美国 NCT00142805 Safety, Tolerability and Efficacy Study of Tricaprilin (AC-1202) Administered for Ninety Days in Subjects With Probable Alzheimer's Disease of Mild to Moderate Severity 三辛酸甘油酯 - 阿尔茨海默症 Alzheimer's Disease Cerecin, Inc. Completed 临床2期 2004-11-04 2007-01-07 美国 10、临床结果 标题 登记号 来源 分期 适应症 评价人数 用药方案 结果 评价 发布日期 申办/合作机构 主要研究药物 来源链接 Synapse链接 Tricaprilin (CER-0001) for the preventive treatment of migraine: A phase 2 randomised, double-blind, placebo-controlled pilot study NCT04437199 Pubmed 临床2期 偏头痛 81 CER-0001 (up to 30 g twice a day) TEAE = 90.0 %  积极 2024-07-01 Cerecin, Inc. 三辛酸甘油酯 https://pubmed.ncbi.nlm.nih.gov/39094432/ https://synapse.zhihuiya.com/clinical-result-detail/9a240a84ee5509aa02888d8e5ea53e22 Tricaprilin (CER-0001) for the preventive treatment of migraine: A phase 2 randomised, double-blind, placebo-controlled pilot study NCT04437199 Pubmed 临床2期 偏头痛 81 Placebo TEAE = 82.9 %  积极 2024-07-01 Cerecin, Inc. 三辛酸甘油酯 https://pubmed.ncbi.nlm.nih.gov/39094432/ https://synapse.zhihuiya.com/clinical-result-detail/9a240a84ee5509aa02888d8e5ea53e22 25 November 2022 Poster presentation on the Metabolic Mechanism in Migraine: Tricaprilin, a Ketogenic Agent NCT04437199 Corporate Publications 临床2期 偏头痛 81 Tricaprylin 头痛时间(3-month) = For Part 1, there was no meaningful difference in the primary endpoint between treatment arms during Month 3.   积极 2022-11-25 Cerecin, Inc. 三辛酸甘油酯 https://cerecin.com/wp-content/uploads/2022/12/AC-20-022-poster_CNS-summit_2022.pdf https://synapse.zhihuiya.com/clinical-result-detail/d2aa2ea2248aa9885ae292229a52955a 25 November 2022 Poster presentation on the Metabolic Mechanism in Migraine: Tricaprilin, a Ketogenic Agent NCT04437199 Corporate Publications 临床2期 偏头痛 81 Placebo 头痛时间(3-month) = For Part 1, there was no meaningful difference in the primary endpoint between treatment arms during Month 3.   积极 2022-11-25 Cerecin, Inc. 三辛酸甘油酯 https://cerecin.com/wp-content/uploads/2022/12/AC-20-022-poster_CNS-summit_2022.pdf https://synapse.zhihuiya.com/clinical-result-detail/d2aa2ea2248aa9885ae292229a52955a A Placebo-Controlled, Parallel-Group, Randomized Clinical Trial of AC-1204 in Mild-to-Moderate Alzheimer's Disease NCT01741194 Pubmed 临床2/3期 阿尔茨海默症 413 AC-1204 ADAS-Cog(11, APOE4 non-carriers) = 0.6 Point  不佳 2020-01-01 Cerecin, Inc. 三辛酸甘油酯 https://pubmed.ncbi.nlm.nih.gov/32310169/ | https://doi.org/10.3233/jad-191302 https://synapse.zhihuiya.com/clinical-result-detail/82da39aea94da5d52805292a58595329 A Placebo-Controlled, Parallel-Group, Randomized Clinical Trial of AC-1204 in Mild-to-Moderate Alzheimer's Disease NCT01741194 Pubmed 临床2/3期 阿尔茨海默症 413 Placebo ADAS-Cog(11, APOE4 non-carriers) = -0.0 Point  不佳 2020-01-01 Cerecin, Inc. 三辛酸甘油酯 https://pubmed.ncbi.nlm.nih.gov/32310169/ | https://doi.org/10.3233/jad-191302 https://synapse.zhihuiya.com/clinical-result-detail/82da39aea94da5d52805292a58595329 Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial NCT00142805 Pubmed 临床2期 阿尔茨海默症 152 AC-1202 ADAS-Cog score = 1.9 Point  积极 2009-08-10 Cerecin, Inc. 三辛酸甘油酯 https://pubmed.ncbi.nlm.nih.gov/19664276/ https://synapse.zhihuiya.com/clinical-result-detail/522e922e983d55aae234ade25583a42d 11、转化医学 研究 亮点 主题 期刊/会议 出版日期 药物 适应症 机构 Using Caprylic Acid for the Prevention and Treatment of Helicobacter pylori Infection and Gastric Cancer: A Review - 药物发现/临床前 Metabolites 2025-09-22 三辛酸甘油酯 幽门螺杆菌感染 | 胃癌 Departamento de Infectómica y Patogénesis Molecular, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Ciudad de México 07360, CDMX, Mexico | rea Académica de Química, Instituto de Ciencias Básicas e Ingeniería, Ciudad del Conocimiento, Universidad Autónoma del Estado de Hidalgo (UAEH), Carretera, Pachuca-Tulancingo Km. 4.5, Mineral de la Reforma 42183, Hidalgo, Mexico | Área Académica de Medicina, Instituto de Ciencias de la Salud, Universidad Autónoma del Estado de Hidalgo, Eliseo Ramírez Ulloa No. 400, Doctores, Pachuca 42090, Hidalgo, Mexico Caprylic Acid Restores Branched-Chain Amino Acid Metabolism in a Mouse Cachexia Model - 药物发现/临床前 Curr Issues Mol Biol 2025-05-01 三辛酸甘油酯 恶病质 Division of Rehabilitation, Hanna Central Hospital, Ikoma 630-0243, Japan | Department of Molecular Pathology, Nara Medical University School of Medicine, Kashihara 634-8521, Japan Letter to the Editor: Tricaprilin (CER-0001) for the preventive treatment of migraine: A phase 2 randomised, double-blind, placebo-controlled pilot study - 2期临床研究 J Neurol Sci 2024-11-01 三辛酸甘油酯 偏头痛 Shaheed Mohtarma Benazir Bhutto Institute of Trauma | Jinnah Post Graduate Medical Centre | Islamabad Medical and Dental College Response to Aanwat et al. on chow et al. Tricaprilin (CER-0001) for the preventive treatment of migraine: A phase 2 randomised, double-blind, placebo-controlled pilot study JONS July 22, 2024 - 2期临床研究 J Neurol Sci 2024-11-01 三辛酸甘油酯 - RWJ Medical School Rutgers University, NJ, United States of America. Electronic address: cantillma@rwjms.rutgers.edu. Caprylic Acid Inhibits High Mobility Group Box-1-Induced Mitochondrial Damage in Myocardial Tubes - 药物发现/临床前 Int J Mol Sci 2024-07-24 三辛酸甘油酯 心肌损伤 Department of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Nara, Japan Tricaprilin (CER-0001) for the preventive treatment of migraine: A phase 2 randomised, double-blind, placebo-controlled pilot study 本研究旨在评估CER-0001作为预防偏头痛的新药物。研究结果显示，CER-0001在2-3个月内呈现积极的方向性效果，尤其在第二个月表现出明显改善。虽然在主要终点上未观察到显著差异，但CER-0001组的退出率较低，且不良事件发生率与安慰剂组相似。未来将采用新配方进行更大规模的2/3期研究。这一研究已在ClinicalTrials.gov进行注册（NCT04437199）。 2期临床研究 Pubmed 2024-07-01 三辛酸甘油酯 偏头痛 Cerecin, Inc.  INVESTIGATIONAL NEW ALZHEIMER'S DRUG TRICAPRILIN: POSSIBLE EFFECTS OF APOEε4 NON-CARRIER SELECTION AND SITE EFFECTS ON STUDY OUTCOMES IN A PHASE 2/3 STUDY IN MILD-TO-MODERATE ALZHEIMER'S DISEASE PATIENTS 本研究旨在探讨新型阿尔茨海默病药物Tricaprilin在轻至中度阿尔茨海默病（AD）患者中的可能效果。研究发现，在前期2b阶段研究中，Tricaprilin对APOE基因ε4等位基因的非携带者显示出显著改善。而在本次26周的2/3期试验中，对413名轻至中度AD患者进行了双盲、随机、安慰剂对照的研究。结果显示，基线MMSE评分在APOEε4携带者中较低，而在未携带者中较高。安慰剂组中，APOEε4携带者的ADAS-Cog评分下降1.2分，而未携带者仅下降0.31分。此外，不同研究地点的未携带者的结果也存在差异。这些发现表明Tricaprilin可能对不同基因型和研究地点产生不同影响，值得进一步研究。 2/3期临床研究 AAIC 2018 2018-07-01 三辛酸甘油酯 阿尔茨海默症 - Investigating the effects of caprylic triglyceride on mitochondrial function in cell models of amyotrophic lateral sclerosis 我们研究了辛酸甘油三酸酯对于肌萎缩侧索硬化症(ALS)细胞模型中线粒体功能的影响。ALS是一种神经退行性疾病，表现为瘫痪、骨骼肌萎缩，最终导致死亡。目前尚无有效的医学治疗方法。我们的研究发现，使用辛酸甘油三酸酯可以延缓ALS小鼠模型的病程，并减少运动神经元的丧失。我们的研究还表明，辛酸甘油三酸酯可以提高细胞线粒体的氧消耗速率（OCR），有可能通过恢复线粒体能量代谢来作为ALS的治疗方法。此外，我们的研究还表明，辛酸甘油三酸酯可能影响线粒体通透性转换孔（mPTP）的功能，mPTP在轴突退行中起重要作用。我们将在细胞模型和小鼠中进行进一步研究，以探究辛酸甘油三酸酯对ALS模型中线粒体功能的作用机制，为临床转化研究提供指导。 药物发现/临床前 SFN 2015 2015-10-20 三辛酸甘油酯 肌萎缩侧索硬化 Neurol., Icahn Sch. of Med. At Mount Sinai, New York, NY; Assessment of caprylic triglyceride for dietary intervention in an amyotrophic lateral sclerosis mouse model 本研究评估了辛酸甘油三酸酯在治疗肌萎缩侧索硬化症（ALS）小鼠模型中的作用。研究发现，辛酸甘油三酸酯可以提高ALS小鼠脊髓线粒体能量代谢，但对运动功能和存活时间没有显著改善作用。因此，辛酸甘油三酸酯可能作为改善ALS代谢效率的联合治疗方法，与靶向运动神经元功能和存活的药物一起使用。 药物发现/临床前 SFN 2011 2011-11-16 三辛酸甘油酯 肌萎缩侧索硬化 Instituto Neurol Goiania Ltda | New York, NY Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial 本研究旨在评估生物医药领域中的酮能药物AC-1202对轻至中度阿尔茨海默病（AD）患者认知功能的影响。研究结果表明，AC-1202显著提高了血清酮体水平，并在ADAS-Cog评分上与安慰剂组相比产生了显著差异。特别是在APOE4(-)患者中，效果最为显著。此外，AC-1202的不良事件主要限于胃肠系统，且多为轻度至中度且短暂的性质。因此，AC-1202可能对AD患者的认知功能产生积极影响，尤其是在APOE4(-)患者中。 2期临床研究 Pubmed 2009-08-10 三辛酸甘油酯 阿尔茨海默症 Cerecin, Inc.